March 20th 2024
The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Immune Checkpoint Inhibitors Approach Frontline Setting in Head and Neck Squamous Cell Cancer
April 5th 2019Immune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.
Read More
Challenges Persist With CAR T-Cell Therapy in Pancreatic Cancer
April 2nd 2019The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Pembrolizumab Receives Priority Review Designation from FDA for Frontline HNSCC
February 12th 2019Based on data from the phase III KEYNOTE-048 trial, pembrolizumab has received a priority review designation from the FDA alone or in combination with platinum and 5-fluorouracil chemotherapy as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Read More
Cemiplimab Combo Does Not Show Superior ORR to Anti-PD-1 Monotherapy in Advanced HNSCC
December 13th 2018The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.
Read More
No Survival Benefit Found With Durvalumab in Head and Neck Cancer
December 10th 2018AstraZeneca has reported that the phase III EAGLE trial has missed its primary endpoint, as patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy did not see a survival benefit with durvalumab alone or combined with tremelimumab.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More